What’s New

Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low- Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan

Read the press release


Save the date – Two Charities, One Goal – Saving Lives

We are excited to announce that R Baby Foundation and Michael’s Mission are collaborating to save lives at a benefit concert on April 4, 2019 at the Hammerstein Ballroom in New York City! The concert will feature exciting entertainment and 1000+ guests all gathered to make an impact and save lives.

Learn more

View All Events